MAIA Biotechnology (MAIA) announced that a manuscript detailing developments in its Phase 2 THIO-101 clinical trial was accepted and published in the international peer-reviewed open access scientific journal, Cells, in a special issue, “Cellular Mechanisms of Anti-Cancer Therapies” MAIA Chairman and CEO Vlad Vitoc, M.D. commented, “The importance of the findings published in Cells cannot be overstated. While conventional immunotherapies have expanded treatment options for patients, intrinsic and acquired resistance by patients remains a challenge. Our novel combination strategy of ateganosine sequenced with a checkpoint inhibitor stands out, showing encouraging results in a population with high unmet medical need.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAIA:
- MAIA Biotechnology Secures European Patent for Cancer Therapy
- MAIA Biotechnology granted European patent for telomere-targeting agents
- MAIA Biotechnology’s Ateganosine Receives FDA Fast Track
- MAIA Biotechnology granted fast track designation for ateganosine
- MAIA Biotechnology Publishes Promising Preclinical Cancer Data